An interventional study of Transcranial Direct Stimulation in COVID-19, sponsored by Istanbul Medipol University Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.
Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in COVID-19 with a site in Turkey — 9 open to participants now, 11 under way, 3 of them phase 3. COVID-19 · Turkey.
Among the 429 studies in COVID-19 with a site in Turkey, this one is the 110th largest by planned enrollment of the 178 interventional ones that give a count, is one of 9 that started in 2023, is one of 123 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 390th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →9 of the 429 studies in COVID-19 with a site in Turkey are open now. Recruiting first, the newest first:
Pfizer · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Turkey, United States, Argentina and 16 more countries
Ages 12+
AstraZeneca · Sites in Turkey, United States, Argentina and 36 more countries
Ages 18+
Gazi University · Sites in Turkey
Ages 18–75
Ankara University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 26 · Phase 3 27 · Phase 4 4
First in 2018; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 64 across the 178 interventional studies, 148 across the 251 observational. Of the 342 that completed or were terminated, 19 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 429 have an industry lead sponsor. The 10 most frequent:
Istanbul Medipol University Hospital is the lead sponsor of 368 studies on the registry; 48 are open to participants now.
Istanbul Medipol University Hospital has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in Turkey that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 429 studies in COVID-19 with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the effects of bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) with active tDCS (transcranial direct stimulation/transcranial direct stimulation) on neurocognitive (memory and executive) functions in patients with Covid-19 infection and subjective cognitive complaints, as well as resting-state fMRI In the case of dfMRI, it is aimed to examine the default mode network (DMN) and parietal memory network (PMN) inter- and intra-network connectivity alterations and the hippocampal region connectivity alterations and contribute to the relevant literature.
The DMN is active when not engaged in a goal-oriented activity and at rest. Resting DNM is especially active when the mind is busy with introspective situations (Barkhof et al., 2014; Mak et al., 2017). Although the posterior parts of the DMN consisting of the posterior cingulate/precuneus and bilateral parietal cortex regions are associated with memory functions, memory functions are not unique to DMN and the parietal regions are not functionally homogeneous (Sestieri et al., 2011). At this point, a new network called the parietal memory network (PMN) was defined in a study by Gilmore (Gilmore et al., 2015). This network is a system that diverges from the posterior parts of the DMN and consists of the middle cingulate cortex, precuneus and inferior parietal lobule/angular gyrus structures and has overlapping regions with the DMN. This network appears to differ from the DMN in different types of recall memory functions. Accordingly, when recalling autobiographical information, DMN; PMN seems to be active in encoding and recall tasks related to recognition memory (McDermott et al., 2009; Chen et al., 2017; Nelson et al., 2013; Hu et al., 2016; Manenti et al., 2010; Kragel et al., 2016) . A double dissociation appears to occur between these two network systems in memory processes, and furthermore, the spacial proximity of PMN to the DMN suggests that some of the cognitive dysfunctions attributed to the DMN of these two systems are due to PMN. The fact that PMN is associated with memory encoding and recall functions even in different types of tasks (de-activity in perceiving new stimulus but being active in perceiving familiar stimulus) differentiates it from other network systems. Stimulation of the parietal region with repetitive transcranial magnetic stimulation (rTMS) resulted in improved visual recognition memory performance (Velioğlu et al., 2021).
The dorsolateral prefrontal cortex (DLPFC) is the central region associated with executive functions, and damage to this region is associated with difficulty in regulating behavioral responses, memory-retrieval, and inability to demonstrate appropriate motor behavior. Damages in this region are associated with cognitive loss in related areas (Liu et al., 2021; Brak et al., 2022). tDCS, on the other hand, stands out as a promising method for patients with Covid-19 infection and subjective cognitive complaints, and appears to act by modulating functional connectivity (Baptista, 2020; Linnhoff, 2023; Yulug B). Increased connectivity between the hippocampus and other DMN nodes such as the dorsal attention network, control, attention-attractiveness network, and sensori-motor networks was detected in fMRI with atDCS stimulation (Manenti et al., 2020; Meinzer et al., 2015). In this context, improvement in neurocognitive tests and changes in functional imaging can be detected with stimulation of the relevant regions of the cortex with tDCS in patients who have had Covid-19 infection and have subjective cognitive complaints. In patients with Covid-19 infection, stimulation of the relevant regions with tDCS resulted in improvement in cognitive functions such as working memory and cognitive control. (Baptista, 2020; Linnhoff, 2023; Yulug B,2023). At this point, DLPFC stimulation may also result in improved cognitive functions regarding encoding and recall.
From this point of view, in this study -based on the studies referenced in the text-, bilateral stimulation of the DLPFC region with anodal tDCS (atDCS) increased performance in neurocognitive abilities, especially memory and executive functions, in patients who had Covid-19 infection and had subjective cognitive complaints. The methodical mesh is shaped in the context of this template, hypothesizing that it will result in In addition, in the fMRI studies mentioned above, it is aimed to point out that tDCS stimulation increases the coherence between DMN networks and to examine the effect of tDCS stimulation on DMN network connectivity and connectivity with the hippocampal region with reference to the role of PMN in patients with Covid-19 infection and subjective cognitive complaints. From this point of view, the aim of this study is dorsolateral prefrontal cortex (DLPFC) active tDCS (transcranial direct stimulation/transcribed) in patients with covid-19 infection and subjective cognitive complaints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.
Procedure: Transcranial Direct Stimulation
For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
Procedure: Transcranial Direct Stimulation
2 mA, 20 min, 5 days
Montreal cognitive assessment
Cognition Test
Time frame: Before Treatment / 1 month after treathment
Cognition Test Material
clock drawing test, digit range test, verbal fluency test, stroop test, trail making test
Time frame: Before Treatment / 1 month after treathment
NPI
Cognition Test (Neuropsychiatric Inventory)
Time frame: Before Treatment / 1 month after treathment
Öktem Verbal Memory Processes Test
Cognition Test
Time frame: Before Treatment / 1 month after treathment
Rey Complex Figure Test
Cognition Test
Time frame: Before Treatment / 1 month after treathment
Ran from Oct 2023 to primary completion in Oct 2024, 12 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 12 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Medipol University Hospital →